0
0
May 2, 2025 – In a groundbreaking advance for global healthcare, artificial intelligence (AI) has helped identify early signs of lung cancer in nearly 50,000 people through the analysis of 5 million chest X-rays across 20 countries. This achievement marks a significant step forward in the fight against one of the world’s deadliest cancers, especially in regions with limited access to advanced medical diagnostics.
Global Collaboration for Early Detection
The AI-powered screening initiative is the result of a collaboration between AstraZeneca, a leading global biopharmaceutical company, and Qure.ai, an Indian health-tech firm specializing in medical imaging solutions. Their proprietary algorithm, known as qXR, was deployed in Asia, the Middle East, Africa, and Latin America-areas where access to radiologists and sophisticated imaging facilities is often scarce.
The qXR algorithm scans chest X-rays for abnormalities, particularly high-risk lung nodules that could indicate early-stage cancer. When such abnormalities are detected, patients are flagged for further diagnostic tests, such as CT scans, enabling earlier intervention and potentially life-saving treatment.
Impact and Expert Insights
“Reaching the five million scan milestone demonstrates the power of digital innovation in transforming cancer care. AI-enabled tools like qXR are proving to be a cost-effective way to screen for lung cancer where radiologists or advanced imaging facilities may not be readily available,” said Ti Hwei How, Vice President of International Oncology at AstraZeneca.
Prashant Warier, CEO of Qure.ai, emphasized the real-world impact of the technology: “This milestone shows how AI can bridge the gap in healthcare access and strengthen systems through faster diagnosis.”
Promising Results and Future Expansion
A recent study presented at the European Lung Cancer Congress 2025 revealed that qXR successfully identified high-risk nodules in 54.1% of cases, underscoring its value as a frontline screening tool. Lung cancer remains the leading cause of cancer-related deaths globally, with the burden especially high in low- and middle-income countries due to limited screening programs.
AstraZeneca and Qure.ai are now partnering with local governments and health agencies to expand the reach of AI-powered screening, aiming to bring timely lung cancer diagnosis to even more underserved communities.
Disclaimer:
This article is based on information reported by India Today on May 1, 2025. The AI screening technology discussed is not a substitute for professional medical advice, diagnosis, or treatment. Individuals should consult qualified healthcare professionals for personal medical concerns. The effectiveness and availability of AI-based screening may vary by region and healthcare system.
Citations:
